S Leah. Etheridge, et.al., JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms., Proceedings of the National Academy of Sciences of the United States of America, 2014, 111

http://rdf.ncbi.nlm.nih.gov/pubmed/24469804

S Leah. Etheridge, et.al., JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms., Proceedings of the National Academy of Sciences of the United States of America, 2014, 111

pubmed

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• increased neutrophil cell number_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0000219IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• increased megakaryocyte cell number_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0008254IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• increased red blood cell distribution width_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0010067IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal blood homeostasis_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0009642IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal erythropoiesis_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0000245IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal bone marrow morphology_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0002397IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal megakaryocyte progenitor cell morphology_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0002413IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal megakaryocyte progenitor cell morphology_Tg(JAK2*V617F)FF1Rsko/0,Tg(Pf4-icre)Q3Rsko/0
  http://metadb.riken.jp/0002413IC57BL6TgJAK2V617FFF1Rsko0TgPf4icreQ3Rsko0TgPf4icreQ3RskoTgJAK2V617FFF1Rsko
• abnormal blood coagulation_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0002551IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• enlarged spleen_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0000691IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• decreased platelet aggregation_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0009549IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal common myeloid progenitor cell morphology_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0006410IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• abnormal response to injury_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0005164IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• osteopetrosis_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0000067IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• decreased T cell number_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0005018IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• increased bleeding time_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0005606IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko
• thrombocytosis_Tg(JAK2*V617F)FF1Rsko/0,Tg(Tek-cre)1Arnd/0
  http://metadb.riken.jp/0005505IC57BL6CBADBA2TgJAK2V617FFF1Rsko0TgTekcre1Arnd0TgTekcre1ArndTgJAK2V617FFF1Rsko